亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

上海楷韌實業有限公司  

普拉格雷等料藥及其中間體

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:徐默然
  • 電話:021-64120566
  • 郵件:shkairen@163.com
  • 傳真:021-64607217
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 鹽酸埃羅替尼CAS:183319-69-9
鹽酸埃羅替尼CAS:183319-69-9
單價 面議對比
詢價 暫無
發貨 上海付款后3天內
品牌 鹽酸埃羅替尼
型號 183319-69-9
規格 醫用級
過期 長期有效
更新 2013-03-25 20:50
 
詳細信息

中文名稱:埃羅替尼鹽酸鹽
英文名稱:Erlotinib hydrochloride
中文別名:伊諾替尼鹽酸鹽;伊諾替尼鹽 酸鹽 ;N-(3-乙炔苯基)-[6,7-二(2-甲氧基乙氧基)]喹唑啉-4-胺鹽酸鹽 ;鹽酸埃羅替尼
英文別名:4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI);6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline  hydrochloride;CP358774;4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1);OSI 774;Tarceva;[6,7-Bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride;Erlotinib HCl;Erlotinib hydrochloride and Intermediate;
CAS   No.:183319-69-9
EINECS號:安全數據
分 子 式:C22H24ClN3O4
分 子 量:429.90
©2025 上海楷韌實業有限公司 版權所有   技術支持:化工網   訪問量:8723  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |